Jump to content

Cobozantinib (Cometriq) poor results in clinical trials

Paul Edwards

Recommended Posts

This post in the New Prostate Cancer Infolink suggests that


"the failure of this drug to demonstrate significant efficacy in either one of two Phase III trials for the treatment of metastatic, castration-resistant prostate cancer has surely ended any attempt to develop this drug for the treatment of prostate cancer."

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...